Skip to content
★ Sign in to follow
Winner Medical Co., Ltd. logo

Winner Medical Co., Ltd. Stock: price and insider trades · China

稳健医疗

CN·Mcap CN¥17.8BHealth Care

No insider purchase over the last 90 days. The latest, by 方修元, was filed 10 Sept 2025.

Winner Medical Co., Ltd.: what insiders have been doing

Headquartered in Longhua District, People's Republic of China, Winner Medical Co., Ltd. belongs to the Health Care sector and traces its origins to 1991. Filings by its managers are published through SSE / SZSE (CSRC). Winner Medical Co., Ltd. has had no insider filing for more than a year; the last one goes back to 10 September 2025.

Over the whole record (from 2022), the tally stands at 9 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
9
Thresholds
n/a
Buy Volume
€4M
9 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
方修元1 buy

Since the insiders bought

  • Filed 10 Sept 2025 · 424 days ago · €3.2M
    -3.7%
    Entry CN¥39.79 · Close at T+90 CN¥38.32
  • Filed 29 May 2024 · 893 days ago · €15k
    +61.5%
    Entry CN¥29.96 · Close at T+365 CN¥48.38
  • Filed 26 Apr 2024 · 926 days ago · €20k
    +52.6%
    Entry CN¥31.78 · Close at T+365 CN¥48.50

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 9,473 of 26,911 companies
58.9
score / 100
Value
58
Quality
60
FCF yld5.7%
Earn yld4.3%
EV/EBITDA11.5x
ROE6.8%
Gross mgn48%
Net mgn7.0%
Debt/EBITDA1.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥30.58
Analyst consensus
4 analysts
·
CN¥32.50Target CN¥37.56(+23%)CN¥40.75
Income statement
RevenueCN¥10.9B
Gross profitCN¥5.2B48% margin
EBITDACN¥1.8B16% margin
Net incomeCN¥768M7.1% margin
Valuation
PER (trailing)22.7x
P/Book1.5x
Beta-0.01
Balance sheet & cash
Market capCN¥17.8B
Total debtCN¥2.5B
Free Cash FlowCN¥1B
Debt / Equity24%
Profitability & ownership
ROE6.8%
ROA4.1%
% insiders71.8%
% institutions3.4%
Last declaration on 10 September 2025
Declarations9 total
  • ▲
    董事,高管Executives
    26M CNY15SZSE
    830,000 shares90.6% of flowA股XSHESZSE:173000009518749300
    Canonical exit: 9 Dec 2025 (T+90)
  • ▲
    监事Executives
    116,960 CNY9SZSE
    4,000 shares17.3% of flowA股XSHESZSE:173000007702228320
    Canonical exit: 27 Aug 2024 (T+90)
  • ▲
    高管Executives
    153,650 CNY28SZSE
    5,000 shares46.5% of flowA股XSHESZSE:173000007573117470
    Canonical exit: 25 Jul 2024 (T+90)
  • ▲
    董秘,高管Executives
    61,820 CNY24SZSE
    2,000 shares7.9% of flowA股XSHESZSE:173000007573117500
    Canonical exit: 25 Jul 2024 (T+90)
  • ▲
    董秘,高管Executives
    388,125 CNY16SZSE
    12,500 shares49.8% of flowA股XSHESZSE:173000007573117400
    Canonical exit: 24 Jul 2024 (T+90)
  • ▲
    高管Executives
    179,500 CNY28SZSE
    5,000 shares53.5% of flowA股XSHESZSE:173000007330443550
    Canonical exit: 19 May 2024 (T+90)
  • ▲
    监事Executives
    561,960 CNY15SZSE
    18,000 shares82.7% of flowA股XSHESZSE:173000007305069570
    Canonical exit: 2 May 2024 (T+90)
  • ▲
    董秘,高管Executives
    301,199 CNY27SZSE
    5,300 shares42.3% of flowA股XSHESZSE:173000005503421760
    Canonical exit: 28 Jul 2022 (T+90)
  • ▲
    董事,高管Executives
    2M CNY8SZSE
    40,000 shares9.4% of flowA股XSHESZSE:173000005464720580
    Canonical exit: 21 Jul 2022 (T+90)

9 of 9 declarations

About Winner Medical Co., Ltd.

稳健医疗 is a company specializing in the healthcare and pharmaceutical sector, providing innovative medical products and services. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations